Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Alter, G. Tegtmeier, B. Jett, S. Quan, J. Shih, W. Bayer, A. Polito (1991)
The use of a recombinant immunoblot assay in the interpretation of anti‐ hepatitis C virus reactivity among prospectively followed patients, implicated donors, and random donorsTransfusion, 31
C. Poel, H. Reesink, J. Boven, H. Cuypers, I. Winkel, P. Exel-Oehlers, W. Schaasberg, P. Lelie, A. Weiner, A. Polito, S. Quan, R. Nello, M. Houghton, D. Mulder-Folkerts, A. Leentvaar‐Kuypers (1991)
Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assayThe Lancet, 337
Alter Alter (1992)
New kit on the block: evaluation of second‐generation assays for detection of antibody to the hepatitis C virus (editorial; comment)Hepatology, 15
D. Surgenor, E. Wallace, Steven Hao, R. Chapman (1990)
Collection and transfusion of blood in the United States, 1982-1988.The New England journal of medicine, 322 23
H. Okamoto, Shunichi Okada, Yasushi Sugiyama, Takeshi Tanaka, Y. Sugai, Y. Akahane, A. Machida, S. Mishiro, H. Yoshizawa, Y. Miyakawa (1990)
Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5'-noncoding region.The Japanese journal of experimental medicine, 60 4
(1986)
Antibody to hcpatitis B core antigen as a paradoxical marker for nonA , non - B hepatitis agents in donated blwd
J. Donahue, A. Muñoz, P. Ness, Donald Brown, D. Yawn, Hugh McAllister, B. Reitz, K. Nelson (1992)
The declining risk of post-transfusion hepatitis C virus infection.The New England journal of medicine, 327 6
H. Alter (1992)
New kit on the block: Evaluation of second‐generation assays for detection of antibody to the hepatitis C virusHepatology, 15
G. Kuo, Q. Choo, H. Alter, G. Gitnick, A. Redeker, R. Purcell, T. Miyamura, J. Dienstag, M. Alter, C. Stevens (1990)
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.Science, 244 4902
Aach Rd, C. Stevens, Hollinger Fb, J. Mosley, D. Peterson, P. Taylor, R. Johnson, L. Barbosa, G. Nemo (1992)
Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays.The New England journal of medicine, 325 19
J. Esteban, António Gonzalez, J. Hernández, L. Viladomiu, C. Sánchez, J. López-Talavera, D. Lucea, C. Martín‐Vega, X. Vidal, R. Esteban, J. Guardia (1990)
Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis.The New England journal of medicine, 323 16
(1956)
Nonparametric statistics for the bchavioral sciences
Nucleic Acids Chcmistry, Alan Polito, PhD, Vice President, Immunodiagnostics, Chiron Chiron Corporation
Alter Alter, Purcell Purcell, Shih Shih (1989)
Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non‐A, non‐B hepatitisN Engl J Med, 321
M. Houghton, A. Weiner, Jang Han, G. Kuo, Q. Choo (1991)
Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral diseaseHepatology, 14
J. McHutchison, J. Person, S. Govindarajan, B. Valinluck, Tessie Gore, Steven Lee, M. Nelles, A. Polito, D. Chien, R. Dinello, S. Quan, G. Kuo, A. Redeker (1992)
Improved detection of hepatitis c virus antibodies in high‐risk populationsHepatology, 15
Q. Choo, G. Kuo, A. Weiner, L. Overby, D. Bradley, M. Houghton (1989)
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.Science, 244 4902
C. Goodman (1988)
The American Association of Blood BanksTransfusion, 2
Irwin Memorial Blood Centers
A new, multiple‐antigen enzyme immunoassay (EIA‐2) for hepatitis C virus (HCV) antibodies was evaluated in parallel with the previously available c100‐3 HCV EIA (EIA‐1) in 14,068 volunteer blood donors as well as in 25 cases of transfusion‐associated hepatitis C for which recipient and donor samples were available. When compared to EIA‐1, the EIA‐2 was more sensitive in detecting HCV‐infected blood donors. The EIA‐2 detected an additional 1 in 1000 EIA‐1‐negative, surrogate marker‐ negative donors who were infected with HCV as demonstrated by polymerase chain reaction (PCR). The specificity of the EIA‐2 was comparable to that of the EIA‐1, but the two tests appear to detect different populations of false‐positive donors. Recombinant immunoblot assay‐indeterminate donors were detected five times more frequently by the EIA‐2; PCR demonstrated that 21 percent of these donors were infected with HCV. The greater sensitivity of EIA‐2 was also found in 25 transfusion recipients with non‐A, non‐B hepatitis; however, in 16 percent of these cases of posttransfusion HCV infection, the EIA‐2 failed to detect an HCV‐seropositive donor. These data indicate that EIA‐2 testing will significantly reduce, but probably not eliminate, the risk of transfusion‐associated HCV infection; we estimate this residual per‐unit risk to be 1 in 2000 to 1 in 6000 units transfused. On a national level, it is projected that the replacement of the anti‐ HCV EIA‐1 with the EIA‐2 will initially prevent up to 40 additional cases of transfusion‐associated hepatitis C per day.
Transfusion – Wiley
Published: Nov 12, 1992
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.